CervoMed Inc (CRVO) Noticias

Form 8-K - Current report

CervoMed Announces Orphan Drug Designation Granted to Neflamapimod by U.S. Food and Drug Administration for the Treatment of Frontotemporal Dementia

Designation underscores significant unmet need in frontotemporal dementia and the potential role of...

Form SC 13G - Statement of Beneficial Ownership by Certain Investors

Form 8-K - Current report

CervoMed Announces Key Senior Leadership Appointments

BOSTON, Nov. 13, 2024 (GLOBE NEWSWIRE) -- CervoMed Inc. (NASDAQ: CRVO), a clinical stage company focused on...

CervoMed Reports Third Quarter 2024 Financial Results and Provides Corporate Updates

- Reported last patient, last visit in its RewinD-LB Phase 2b clinical trial evaluating neflamapimod in...

CervoMed Awarded the Prix Galien USA 2024 Prize for Best Startup

The Prix Galien USA Best Startup category recognizes outstanding innovation by therapeutics-focused life...

CervoMed to Participate in Upcoming Investor Conferences

BOSTON, Nov. 07, 2024 (GLOBE NEWSWIRE) -- CervoMed Inc. (NASDAQ: CRVO), a clinical stage company focused on...

Form 8-K - Current report

CervoMed Announces Key Takeaways from Oral Presentations at the 17th Clinical Trials on Alzheimer's Disease Conference (CTAD)

Data from the AscenD-LB Phase 2a trial in DLB confirm recent scientific literature indicating that plasma glial...

Form 8-K - Current report

CervoMed to Deliver Oral Presentation at the 8th International Lewy Body Dementia Conference

Topline data from the RewinD-LB Phase 2b study on track for December 2024 Detailed safety and efficacy data...

Form 8-K - Current report

CervoMed Announces Last Patient Last Visit in Phase 2b RewinD-LB Trial of Neflamapimod for the Treatment of Early-Stage Dementia with Lewy Bodies (DLB)

• On track to report topline data from the Phase 2b trial in December 2024 • Neflamapimod has the potential to...

Form 424B3 - Prospectus [Rule 424(b)(3)]